Table 1.
Clinicopathological parameters and FEZF1‐AS1 expression in EOC patients
| Characteristics | Total number | FEZF1‐AS1 expression | P‐value | |
|---|---|---|---|---|
| High | Low | |||
| n (%) | n (%) | |||
| Age | ||||
| <55 | 27 | 15 (55.6) | 12 (44.4) | .427 |
| ≥55 | 25 | 15 (60.0) | 10 (40.0) | |
| Differentiation | ||||
| Well | 18 | 9 (50.0) | 9 (50.0) | .105 |
| Moderate | 21 | 14 (66.7) | 7 (33.3) | |
| Poor | 13 | 7 (53.8) | 6 (46.2) | |
| Menopause | ||||
| Pre‐ | 24 | 12 (50.0) | 12 (50.0) | .178 |
| Post‐ | 28 | 18 (64.3) | 10 (35.7) | |
| Depth of invasion | ||||
| T1‐T3 | 20 | 5 (25.0) | 15 (75.0) | .004 |
| T4 | 32 | 25 (78.1) | 7 (21.9) | |
| Lymph node metastasis | ||||
| Absent (NO) | 18 | 6 (33.3) | 12 (66.7) | <.001 |
| Present (N1‐N3) | 34 | 24 (70.6) | 10 (29.4) | |
| Distant metastasis | ||||
| Absent (M0) | 17 | 4 (23.5) | 13 (76.5) | .021 |
| Present (M1‐M3) | 35 | 26 (74.3) | 9 (26.7) | |
| TNM stage | ||||
| I‐II | 19 | 4 (21.1) | 15 (78.9) | <.001 |
| III‐IV | 33 | 26 (78.8) | 7 (21.2) | |
| FIGO Stage | ||||
| I‐ II | 21 | 16 (76.2) | 5 (23.8) | .008 |
| III‐IV | 31 | 14 (45.2) | 17 (54.8) | |